Home/Filings/4/0001646423-25-000007
4//SEC Filing

Wright Richard M. 4

Accession 0001646423-25-000007

CIK 0000744218other

Filed

Nov 16, 7:00 PM ET

Accepted

Nov 17, 4:17 PM ET

Size

16.5 KB

Accession

0001646423-25-000007

Insider Transaction Report

Form 4
Period: 2025-11-13
Transactions
  • Exercise/Conversion

    Common Stock

    2025-11-13$9.02/sh+6,876$61,99727,709 total
  • Exercise/Conversion

    Common Stock

    2025-11-13$10.38/sh+26,672$276,85554,381 total
  • Exercise/Conversion

    Common Stock

    2025-11-13$22.48/sh+15,750$354,06070,131 total
  • Sale

    Common Stock

    2025-11-13$24.00/sh49,298$1,183,17720,833 total
  • Exercise/Conversion

    Incentive Stock Option

    2025-11-136,8760 total
    Exercise: $9.02Exp: 2028-06-13Common Stock (6,876 underlying)
  • Exercise/Conversion

    Incentive Stock Option

    2025-11-1315,7507,875 total
    Exercise: $22.48Exp: 2032-06-16Common Stock (15,750 underlying)
  • Exercise/Conversion

    Incentive Stock Option

    2025-11-1326,6720 total
    Exercise: $10.38Exp: 2030-06-18Common Stock (26,672 underlying)
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  • [F2]As of June 13, 2022, the option is fully vested.
  • [F3]As of June 18, 2024, the option is fully vested.
  • [F4]25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Issuer

Celldex Therapeutics, Inc.

CIK 0000744218

Entity typeother

Related Parties

1
  • filerCIK 0001646423

Filing Metadata

Form type
4
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 4:17 PM ET
Size
16.5 KB